Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialResearch in context
Summary: Background: Inhaled molecular hydrogen gas (H2) has been shown to improve outcomes in animal models of cardiac arrest (CA). H2 inhalation is safe and feasible in patients after CA. We investigated whether inhaled H2 would improve outcomes after out-of-hospital CA (OHCA). Methods: HYBRID II...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537023000846 |
| _version_ | 1827987146914398208 |
|---|---|
| author | Tomoyoshi Tamura Masaru Suzuki Koichiro Homma Motoaki Sano Ryoji Iizuka Hiromichi Narimiya Ryosuke Tsuruta Kotaro Kaneda Motoki Fujita Junichi Sasaki Osamu Akasaka Keisuke Sawai Makiko Nozaki Hiroshi Imai Ken Ishikura Kaoru Ikejiri Yasuyuki Kakihana Shuhei Niiyama Takahiro Futatsuki Masahiro Honda Yasuhiro Ikeda Hideo Oka Hideaki Yoshihara Hirokazu Onishi Susumu Yamashita Koki Shimizu Toshihiro Sakurai Shu Yamada Hiroshi Fukami Nobuaki Shime Kei Suzuki Yasuhiro Kuroda Kenya Kawakita Akio Kimura Tatsuki Uemura Kiyotsugu Takuma Kunio Kanao Youichi Yanagawa Ikuto Takeuchi |
| author_facet | Tomoyoshi Tamura Masaru Suzuki Koichiro Homma Motoaki Sano Ryoji Iizuka Hiromichi Narimiya Ryosuke Tsuruta Kotaro Kaneda Motoki Fujita Junichi Sasaki Osamu Akasaka Keisuke Sawai Makiko Nozaki Hiroshi Imai Ken Ishikura Kaoru Ikejiri Yasuyuki Kakihana Shuhei Niiyama Takahiro Futatsuki Masahiro Honda Yasuhiro Ikeda Hideo Oka Hideaki Yoshihara Hirokazu Onishi Susumu Yamashita Koki Shimizu Toshihiro Sakurai Shu Yamada Hiroshi Fukami Nobuaki Shime Kei Suzuki Yasuhiro Kuroda Kenya Kawakita Akio Kimura Tatsuki Uemura Kiyotsugu Takuma Kunio Kanao Youichi Yanagawa Ikuto Takeuchi |
| author_sort | Tomoyoshi Tamura |
| collection | DOAJ |
| description | Summary: Background: Inhaled molecular hydrogen gas (H2) has been shown to improve outcomes in animal models of cardiac arrest (CA). H2 inhalation is safe and feasible in patients after CA. We investigated whether inhaled H2 would improve outcomes after out-of-hospital CA (OHCA). Methods: HYBRID II is a prospective, multicentre, randomised, double-blind, placebo-controlled trial performed at 15 hospitals in Japan, between February 1, 2017, and September 30, 2021. Patients aged 20–80 years with coma following cardiogenic OHCA were randomly assigned (1:1) using blinded gas cylinders to receive supplementary oxygen with 2% H2 or oxygen (control) for 18 h. The primary outcome was the proportion of patients with a 90-day Cerebral Performance Category (CPC) of 1 or 2 assessed in a full-analysis set. Secondary outcomes included the 90-day score on a modified Rankin scale (mRS) and survival. HYBRID II was registered with the University Hospital Medical Information Network (registration number: UMIN000019820) and re-registered with the Japan Registry for Clinical Trials (registration number: jRCTs031180352). Findings: The trial was terminated prematurely because of the restrictions imposed on enrolment during the COVID-19 pandemic. Between February 1, 2017, and September 30, 2021, 429 patients were screened for eligibility, of whom 73 were randomly assigned to H2 (n = 39) or control (n = 34) groups. The primary outcome, i.e., a CPC of 1 or 2 at 90 days, was achieved in 22 (56%) and 13 (39%) patients in the H2 and control groups (relative risk compared with the control group, 0.72; 95% CI, 0.46–1.13; P = 0.15), respectively. Regarding the secondary outcomes, median mRS was 1 (IQR: 0–5) and 5 (1–6) in the H2 and control groups, respectively (P = 0.01). An mRS score of 0 was achieved in 18 (46%) and 7 (21%) patients in the H2 and control groups, respectively (P = 0.03). The 90-day survival rate was 85% (33/39) and 61% (20/33) in the H2 and control groups, respectively (P = 0.02). Interpretation: The increase in participants with good neurological outcomes following post-OHCA H2 inhalation in a selected population of patients was not statistically significant. However, the secondary outcomes suggest that H2 inhalation may increase 90-day survival without neurological deficits. Funding: Taiyo Nippon Sanso Corporation. Translation: For the Japanese translation of the abstract see Supplementary Materials section. |
| first_indexed | 2024-04-09T23:42:24Z |
| format | Article |
| id | doaj.art-1e6b7c5ab9e0420287f8c7830c70c25e |
| institution | Directory Open Access Journal |
| issn | 2589-5370 |
| language | English |
| last_indexed | 2024-04-09T23:42:24Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj.art-1e6b7c5ab9e0420287f8c7830c70c25e2023-03-18T04:42:35ZengElsevierEClinicalMedicine2589-53702023-04-0158101907Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialResearch in contextTomoyoshi Tamura0Masaru Suzuki1Koichiro Homma2Motoaki Sano3Ryoji IizukaHiromichi NarimiyaRyosuke TsurutaKotaro KanedaMotoki FujitaJunichi SasakiOsamu AkasakaKeisuke SawaiMakiko NozakiHiroshi ImaiKen IshikuraKaoru IkejiriYasuyuki KakihanaShuhei NiiyamaTakahiro FutatsukiMasahiro HondaYasuhiro IkedaHideo OkaHideaki YoshiharaHirokazu OnishiSusumu YamashitaKoki ShimizuToshihiro SakuraiShu YamadaHiroshi FukamiNobuaki ShimeKei SuzukiYasuhiro KurodaKenya KawakitaAkio KimuraTatsuki UemuraKiyotsugu TakumaKunio KanaoYouichi YanagawaIkuto TakeuchiDepartment of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan; Center for Molecular Hydrogen Medicine, Keio University, Tokyo, JapanCenter for Molecular Hydrogen Medicine, Keio University, Tokyo, Japan; Department of Emergency Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan; Corresponding author. Department of Emergency Medicine, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa City, Chiba 272-85, Japan.Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan; Center for Molecular Hydrogen Medicine, Keio University, Tokyo, JapanCenter for Molecular Hydrogen Medicine, Keio University, Tokyo, Japan; Department of Cardiology, Keio University School of Medicine, Tokyo, JapanSummary: Background: Inhaled molecular hydrogen gas (H2) has been shown to improve outcomes in animal models of cardiac arrest (CA). H2 inhalation is safe and feasible in patients after CA. We investigated whether inhaled H2 would improve outcomes after out-of-hospital CA (OHCA). Methods: HYBRID II is a prospective, multicentre, randomised, double-blind, placebo-controlled trial performed at 15 hospitals in Japan, between February 1, 2017, and September 30, 2021. Patients aged 20–80 years with coma following cardiogenic OHCA were randomly assigned (1:1) using blinded gas cylinders to receive supplementary oxygen with 2% H2 or oxygen (control) for 18 h. The primary outcome was the proportion of patients with a 90-day Cerebral Performance Category (CPC) of 1 or 2 assessed in a full-analysis set. Secondary outcomes included the 90-day score on a modified Rankin scale (mRS) and survival. HYBRID II was registered with the University Hospital Medical Information Network (registration number: UMIN000019820) and re-registered with the Japan Registry for Clinical Trials (registration number: jRCTs031180352). Findings: The trial was terminated prematurely because of the restrictions imposed on enrolment during the COVID-19 pandemic. Between February 1, 2017, and September 30, 2021, 429 patients were screened for eligibility, of whom 73 were randomly assigned to H2 (n = 39) or control (n = 34) groups. The primary outcome, i.e., a CPC of 1 or 2 at 90 days, was achieved in 22 (56%) and 13 (39%) patients in the H2 and control groups (relative risk compared with the control group, 0.72; 95% CI, 0.46–1.13; P = 0.15), respectively. Regarding the secondary outcomes, median mRS was 1 (IQR: 0–5) and 5 (1–6) in the H2 and control groups, respectively (P = 0.01). An mRS score of 0 was achieved in 18 (46%) and 7 (21%) patients in the H2 and control groups, respectively (P = 0.03). The 90-day survival rate was 85% (33/39) and 61% (20/33) in the H2 and control groups, respectively (P = 0.02). Interpretation: The increase in participants with good neurological outcomes following post-OHCA H2 inhalation in a selected population of patients was not statistically significant. However, the secondary outcomes suggest that H2 inhalation may increase 90-day survival without neurological deficits. Funding: Taiyo Nippon Sanso Corporation. Translation: For the Japanese translation of the abstract see Supplementary Materials section.http://www.sciencedirect.com/science/article/pii/S2589537023000846Out-of-hospital cardiac arrestHydrogen inhalationComaReperfusion injury |
| spellingShingle | Tomoyoshi Tamura Masaru Suzuki Koichiro Homma Motoaki Sano Ryoji Iizuka Hiromichi Narimiya Ryosuke Tsuruta Kotaro Kaneda Motoki Fujita Junichi Sasaki Osamu Akasaka Keisuke Sawai Makiko Nozaki Hiroshi Imai Ken Ishikura Kaoru Ikejiri Yasuyuki Kakihana Shuhei Niiyama Takahiro Futatsuki Masahiro Honda Yasuhiro Ikeda Hideo Oka Hideaki Yoshihara Hirokazu Onishi Susumu Yamashita Koki Shimizu Toshihiro Sakurai Shu Yamada Hiroshi Fukami Nobuaki Shime Kei Suzuki Yasuhiro Kuroda Kenya Kawakita Akio Kimura Tatsuki Uemura Kiyotsugu Takuma Kunio Kanao Youichi Yanagawa Ikuto Takeuchi Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialResearch in context EClinicalMedicine Out-of-hospital cardiac arrest Hydrogen inhalation Coma Reperfusion injury |
| title | Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialResearch in context |
| title_full | Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialResearch in context |
| title_fullStr | Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialResearch in context |
| title_full_unstemmed | Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialResearch in context |
| title_short | Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trialResearch in context |
| title_sort | efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post cardiac arrest care hybrid ii a multi centre randomised double blind placebo controlled trialresearch in context |
| topic | Out-of-hospital cardiac arrest Hydrogen inhalation Coma Reperfusion injury |
| url | http://www.sciencedirect.com/science/article/pii/S2589537023000846 |
| work_keys_str_mv | AT tomoyoshitamura efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT masarusuzuki efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT koichirohomma efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT motoakisano efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT ryojiiizuka efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT hiromichinarimiya efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT ryosuketsuruta efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT kotarokaneda efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT motokifujita efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT junichisasaki efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT osamuakasaka efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT keisukesawai efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT makikonozaki efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT hiroshiimai efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT kenishikura efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT kaoruikejiri efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT yasuyukikakihana efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT shuheiniiyama efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT takahirofutatsuki efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT masahirohonda efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT yasuhiroikeda efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT hideooka efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT hideakiyoshihara efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT hirokazuonishi efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT susumuyamashita efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT kokishimizu efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT toshihirosakurai efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT shuyamada efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT hiroshifukami efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT nobuakishime efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT keisuzuki efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT yasuhirokuroda efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT kenyakawakita efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT akiokimura efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT tatsukiuemura efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT kiyotsugutakuma efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT kuniokanao efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT youichiyanagawa efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext AT ikutotakeuchi efficacyofinhaledhydrogenonneurologicaloutcomefollowingbrainischaemiaduringpostcardiacarrestcarehybridiiamulticentrerandomiseddoubleblindplacebocontrolledtrialresearchincontext |